1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY, CA
Terns Pharmaceuticals Enters Merger Agreement with Merck Sharp & Dohme
FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
Ex-99.1
Amendment to Exclusive Option and License Agreement with Hansoh
Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
Announces Pricing of Upsized $650 Million Public Offering
Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting
Financial Results, Press Release
FY 2025
Q3
Q2
Q1
FY 2024
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Issuer
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 14D-9 Solicitation/Recommendation Statement
Automatic Shelf Registration Statement
Post-Effective Amendment to Registration Statement
S-8 POS